<![CDATA[Vilamakitug Plus Chemo Meets Survival Threshold in Refractory Metastatic CRC]]>

Data Readoutpositivevilamakitugtrifluridine/tipiracilPositive

AI Analysis

Summary

The anti–IL-1α antibody vilamakitug combined with trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer. The article excerpt does not specify trial phase, sponsor, or patient numbers.

Clinical Trial Data

Outcome Details

Vilamakitug (anti–IL-1α antibody) added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.

Importance:5/10

Sentiment:

0.60

oncologycolorectal cancerclinical trial dataanti-IL-1αoverall survivalrefractory mCRC

Read the original article

Published by Cancer Network on October 19, 2026 3:30 PM

Read Original